Drug Search Results
More Filters [+]

Osanetant

Alternative Names: osanetant, acer-801, acer801, acer 801
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Acer Therapeutics
Company Location: NEWTON MA 02458
Company CEO: Chris Schelling
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Osanetant

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hot Flashes|Menopause

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACER-801-201

P2

Completed

Hot Flashes|Menopause

2023-03-04

Recent News Events